Pain specialist Zogenix has appointed former Pfizer VP R Scott Shively as its new chief commercial officer.
Shively has experience in the therapy area, serving as VP global commercial disease area lead for pain at Pfizer, and we will have responsibility for all of Zogenix’ commercial strategies and operations.
This includes ensuring the success of current products, such as Sumavel DosePro for migraine, as well as soon to be launched products, such as Zohydro, which is pending FDA approval for the treatment of chronic pain.
“We have the potential of launching a new product, expanding our commercial organisation and pursuing a range of corporate development opportunities,” said Roger Hawley, CEO of Zogenix.
“Scott’s commercial expertise will add important depth and breadth to our executive team. He understands our vision as well as the challenges and opportunities we face.”
Prior to his most recent role at Pfizer, Shively spend a year at the US pharma firm as VP, global commercial medicine team leader.
Other previous positions include senior VP commercial operations at pain specialists Alpharma Pharmaceuticals, VP marketing at Endo Pharmaceuticals and VP global strategy and commercial development at Mallinckrodt.
He said: “I believe my experience, not only in the pain market but also with partnering opportunities and successfully building brands, will provide benefits now and into the next phase of the company’s growth. It’s an exciting time to join and to make a contribution to the ongoing success of Zogenix.”